Price T Rowe Associates Inc Kymera Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,870,333 shares of KYMR stock, worth $257 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
6,870,333
Previous 6,645,474
3.38%
Holding current value
$257 Million
Previous $315 Million
12.12%
% of portfolio
0.03%
Previous 0.04%
Shares
17 transactions
Others Institutions Holding KYMR
# of Institutions
186Shares Held
65.5MCall Options Held
49.6KPut Options Held
17K-
Baker Bros. Advisors LP New York, NY6MShares$224 Million2.67% of portfolio
-
Wellington Management Group LLP Boston, MA5.31MShares$199 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$193 Million7.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.15MShares$193 Million3.02% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$183 Million32.49% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.05B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...